BioSpace News Archive

AlivaMab Discovery Services, a leader in the discovery of superior antibody therapeutics, announced an expanded agreement with IGM Biosciences.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that the U.S. Food and Drug Administration has accepted the New Drug Application for Maxigesic® IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain.

The SanBio Group, hereby announce that data comparing outcome measures for persons with traumatic brain injury living with chronic motor deficits was published in Expert Review of Neurotherapeutics.

A mental disorder can be explained as a psychological anomaly that is reflected in patient’s behavior through disability, distress, or any conduct that is not considered as normal mental development.

7 Hills Pharma LLC today announced that it has successfully completed its Phase I clinical trial to evaluate 7HP349, their lead molecule.

ReValve Solutions, Inc., an innovator in the field of transcatheter structural heart replacement and repair, announced it has successfully completed the first human use of its transcatheter, Palmetto System for mitral valve replacement.

Transplant Genomics, the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to announce that over 500 patients have been enrolled in the TRULO observational study.

Mirum Pharmaceuticals, Inc. announced that new data will be presented at the American Association for the Study of Liver Disease annual congress, The Liver Meeting®, November 12-15, 2021.

Arbutus Biopharma Corporation announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleoside analogue therapy at The American Association for the Study of Liver Diseases – The Liver Meeting® 2021 – The Digital Experience™, taking place from November 12-15, 2021.

Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced that it will report its financial results for the third quarter, ended September 30, 2021.